Lance Leopold

3.7k total citations
50 papers, 2.8k citations indexed

About

Lance Leopold is a scholar working on Oncology, Biological Psychiatry and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lance Leopold has authored 50 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 15 papers in Biological Psychiatry and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lance Leopold's work include Tryptophan and brain disorders (15 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Lung Cancer Treatments and Mutations (7 papers). Lance Leopold is often cited by papers focused on Tryptophan and brain disorders (15 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Lung Cancer Treatments and Mutations (7 papers). Lance Leopold collaborates with scholars based in United States, Canada and United Kingdom. Lance Leopold's co-authors include Janet Maleski, Thomas F. Gajewski, Mark S. Berger, Roel Willemze, Robert Newton, Jason Clark, Yufan Zhao, Omid Hamid, John M. Bennett and Eric L. Sievers and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lance Leopold

50 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lance Leopold United States	24	1.4k	1.1k	594	473	435	50	2.8k
Hyo S. Han United States	28	1.4k 1.0×	874 0.8×	349 0.6×	64 0.1×	810 1.9×	146	2.5k
Ji Yuan Wu United States	21	666 0.5×	712 0.6×	168 0.3×	908 1.9×	256 0.6×	44	2.1k
Ben Markman Australia	24	1.2k 0.9×	1.3k 1.2×	219 0.4×	71 0.2×	489 1.1×	75	2.5k
Mohit Trikha United States	29	930 0.7×	1.2k 1.1×	402 0.7×	574 1.2×	227 0.5×	55	2.5k
Gargi D. Basu United States	20	977 0.7×	793 0.7×	510 0.9×	40 0.1×	244 0.6×	53	2.0k
Lili Yang China	26	616 0.4×	944 0.9×	733 1.2×	140 0.3×	316 0.7×	112	2.1k
Rebecca Kristeleit United Kingdom	27	1.6k 1.2×	1.4k 1.3×	364 0.6×	41 0.1×	326 0.7×	147	2.9k
Rita Chiari Italy	36	2.6k 1.9×	1.4k 1.3×	452 0.8×	46 0.1×	2.4k 5.4×	140	4.2k
Yong Wha Moon South Korea	22	918 0.7×	658 0.6×	301 0.5×	22 0.0×	685 1.6×	69	1.8k
Kenneth H. Shain United States	26	1.7k 1.2×	1.7k 1.5×	918 1.5×	1.2k 2.6×	118 0.3×	144	3.4k

Countries citing papers authored by Lance Leopold

Since Specialization

Citations

This map shows the geographic impact of Lance Leopold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lance Leopold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lance Leopold more than expected).

Fields of papers citing papers by Lance Leopold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lance Leopold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lance Leopold. The network helps show where Lance Leopold may publish in the future.

Co-authorship network of co-authors of Lance Leopold

This figure shows the co-authorship network connecting the top 25 collaborators of Lance Leopold. A scholar is included among the top collaborators of Lance Leopold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lance Leopold. Lance Leopold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cho, Byoung Chul, Irene Braña, Beatriz Cirauqui, et al.. (2024). Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. BMC Cancer. 23(S1). 1254–1254. 5 indexed citations

Boyer, Michael, Rina Hui, Philip R. Clingan, et al.. (2024). Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study. BMC Cancer. 23(S1). 1250–1250. 5 indexed citations

Barcellini, Wilma, Fabrizio Pane, Andrea Patriarca, et al.. (2024). Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open‐label study. American Journal of Hematology. 99(12). 2313–2320. 2 indexed citations

Yamamoto, Noboru, Miyako Satouchi, Toshihiko Doi, et al.. (2024). KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer. Investigational New Drugs. 42(3). 261–271. 3 indexed citations

Naing, Aung, John D. Powderly, John Nemunaitis, et al.. (2022). Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. Journal for ImmunoTherapy of Cancer. 10(3). e004223–e004223. 12 indexed citations

Doi, Toshihiko, Yutaka Fujiwara, Kohei Shitara, et al.. (2020). The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434). Investigational New Drugs. 39(1). 152–162. 10 indexed citations

Shi, Jack, Kevin Bowman, Xuejun Chen, et al.. (2016). Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies. The Journal of Clinical Pharmacology. 57(6). 720–729. 13 indexed citations

Hurwitz, Herbert I., Nikhil Uppal, Stephanie A. Wagner, et al.. (2015). Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. Journal of Clinical Oncology. 33(34). 4039–4047. 237 indexed citations

Beatty, Gregory L., Peter J. O’Dwyer, Jason Clark, et al.. (2013). Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.. Journal of Clinical Oncology. 31(15_suppl). 3025–3025. 34 indexed citations

10.

Pond, Gregory R., Andrew J. Armstrong, Brian Wood, et al.. (2012). Ability of C‐reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel‐based chemotherapy. British Journal of Urology. 110(11b). E461–8. 25 indexed citations

11.

Talpaz, Moshe, Ronald Paquette, Lawrence B. Afrin, et al.. (2012). Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts. Blood. 120(21). 176–176. 10 indexed citations

12.

Pond, Gregory R., William R. Berry, Matthew D. Galsky, et al.. (2012). Neutropenia as a Potential Pharmacodynamic Marker for Docetaxel-Based Chemotherapy in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 10(4). 239–245. 16 indexed citations

13.

Pond, Gregory R., Andrew J. Armstrong, Matthew D. Galsky, et al.. (2012). Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials. Urologic Oncology Seminars and Original Investigations. 31(8). 1457–1463. 10 indexed citations

14.

Pond, Gregory R., Andrew J. Armstrong, Brian Wood, et al.. (2012). Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC).. Journal of Clinical Oncology. 30(5_suppl). 204–204. 1 indexed citations

15.

Ready, Neal, Nina Karaseva, С. В. Орлов, et al.. (2011). Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(4). 781–785. 74 indexed citations

16.

Heist, Rebecca S., Julian R. Molina, Lecia V. Sequist, et al.. (2010). Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer. Journal of Thoracic Oncology. 5(10). 1637–1643. 64 indexed citations

17.

Liu, Glenn, et al.. (2009). An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer. Clinical Cancer Research. 15(9). 3172–3176. 146 indexed citations

18.

Larson, Richard A., Eric L. Sievers, Edward A. Stadtmauer, et al.. (2005). Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence. Cancer. 104(7). 1442–1452. 322 indexed citations

19.

Leopold, Lance, et al.. (2002). Acute and Long-Term Toxicities Associated with Gemtuzumab Ozogamicin (Mylotarg®) Therapy of Acute Myeloid Leukemia. Clinical Lymphoma. 2. S29–S34. 29 indexed citations

20.

Leopold, Lance & Roel Willemze. (2002). The Treatment of Acute Myeloid Leukemia in First Relapse: A Comprehensive Review of the Literature. Leukemia & lymphoma. 43(9). 1715–1727. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact